查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1869768

腎臟生物標記市場規模、佔有率和趨勢分析報告：按生物標記、診斷技術、最終用途、地區和細分市場預測（2025-2033 年）

Renal Biomarkers Market Size, Share & Trends Analysis Report By Biomarkers (Functional Biomarkers, Upregulated Proteins), By Diagnostic Technique (ELISA, Immunoassays), By End Use (Hospitals & Clinics), By Region, And Segment Forecasts, 2025 - 2033
出版日期: | 出版商: Grand View Research | 英文 150 Pages | 商品交期: 2-10個工作天內

價格

腎臟生物標記市場摘要

2024年全球腎臟生物標記市場規模估計為15.3億美元，預計2033年將達到31.614億美元。

預計從 2025 年到 2033 年，該市場將以 8.54% 的複合年成長率成長。腎臟疾病，特別是慢性腎臟病(CKD) 和急性腎損傷 (AKI) 的日益普遍，以及臨床上迫切需要超越傳統檢測法的更早、更精確的檢測，正在推動市場成長。

慢性腎臟病（CKD）通常在晚期之前沒有症狀，因此人們對能夠揭示潛在疾病和早期損害的生物標記產生了濃厚的興趣。據估計，美國約有3550萬成年人患有慢性腎臟病，其中許多人對此毫不知情。在全球範圍內，CKD影響約8.5億人，約佔成年人口的9%。一項2024年的研究預測，到2032年，八個主要國家將有近1.25億人發展進行性CKD，比2022年增加25%。Astra Zeneca於2024年4月發布的IMPACT CKD建模研究預測，到2032年，八個國家高達16.5%的人口可能受到慢性腎臟病的影響，其中晚期病例將增加高達59.3%。在布宜諾斯艾利斯舉行的2024年國際腎臟病學會世界腎臟病大會（WCN'24）上公佈的研究結果強調了慢性腎臟病（CKD）作為日益嚴重的全球健康挑戰及其對經濟和環境的重大影響。龐大且不斷成長的腎臟病患者群體，使得對更靈敏、更特異、更全面的生物標記檢測的需求持續成長。此外，糖尿病和高血壓等合併症以及人口老化進一步加重了腎臟負擔，迫使臨床醫生和支付方在疾病早期階段採用先進的生物標記（例如NGAL、KIM-1和Cystatin C ），以改善預後、治療方法分層和後續觀察。早期CKD未確診率高（高達90%的病例可能在腎功能下降之前被漏診），凸顯了在傳統指標（eGFR、肌酐）出現顯著偏差之前，能夠可靠預警早期損害的工具的市場潛力。

腎臟生物標記領域最具吸引力的機會之一在於新興市場（亞洲、拉丁美洲和非洲）。這些地區高血壓和糖尿病盛行率不斷上升，人口老化加劇，導致腎臟疾病負擔加重，但其診斷基礎設施仍不完善。由於許多地區的診斷設備普及率仍然較低，因此，推廣經濟實惠的即時診斷生物標記平台具有巨大的成長潛力。例如，Sphingotec 與 Beckman Coulter 等公司合作，在標準臨床檢測平台上發布了 penKid 檢測，這表明仍處於研究階段的生物標記如何規模化應用於廣泛的臨床實踐（請參閱關於 penKid 在中心檢查室獲得許可和部署的新聞）。在分散式環境中部署多重檢測、低通量檢測或更簡單的快速檢測，有助於彌合服務不足地區的診斷缺口。

與此同時，平台的多樣性正在不斷擴展。雖然酵素免疫分析法（ELISA）仍佔據主導地位，但靈敏度更高的化學冷光免疫檢測、多重檢測、液相層析質譜聯用（LC-MS）、微流體技術和照護現場免疫診斷設備正日益受到關注。例如，貝克曼庫爾特公司在其免疫檢測平台上應用PenKid檢測，就展示如何將新型生物標記整合到檢查室工作流程中。在研究領域，微流體和多體學平台支援新型生物標記的發現和多重檢測，為生物標記公司提供增值分析、軟體和解讀服務提供了可能。

目錄

第1章 腎臟生物標記市場：調查方法與範圍

2. 腎臟生物標記市場：執行摘要

  • 市場概述
  • 細分市場簡介
  • 競爭格局概覽

3. 腎臟生物標記市場變數、趨勢和範圍

  • 市場區隔和範圍
  • 市場體系展望
    • 母市場展望
    • 相關/輔助市場展望
  • 市場動態
    • 市場促進因素分析
    • 市場限制因素分析
  • 全球基於生物標記的免疫檢測市場分析工具
    • 產業分析—波特五力分析
    • PESTEL 分析

第4章 腎臟生物標記市場：生物標記估算與趨勢分析

  • 腎臟生物標記市場：生物標記變異分析
  • 試劑盒和檢測
  • 試劑
  • 服務
  • 功能性生物標記
    • 血清肌酸酐
    • 血中尿素氮（BUN）
    • 估算腎絲球過濾率（eGFR）
  • 上調蛋白
    • 腎損傷分子-1 (KIM-1)
    • 嗜中性白血球明膠酶相關脂質運載蛋白（NGAL）
    • Cystatin C
    • 白細胞介素-18 (IL-18)
    • 其他
  • 其他新型生物標記
    • 微型RNA生物標記
    • 蛋白質體/代謝體學標記物

第5章 腎臟生物標記市場：診斷技術/平台估算與趨勢分析

  • 腎臟生物標記市場：診斷技術/平台差異分析
  • 酵素免疫分析法（ELISA）
  • 分子診斷
  • 免疫檢測
  • 臨床化學檢測
  • 就地檢驗（POC​​T）設備
  • 其他新興平台

6. 腎臟生物標記市場：終端用戶需求預測及趨勢分析

  • 腎臟生物標記市場：終端用途差異分析
  • 醫院和診所
  • 診斷實驗室
  • 學術研究機構
  • 製藥和生物技術公司
  • 其他

7. 腎臟生物標記市場：區域業務分析

  • 區域市場概況
  • 北美洲
  • 歐洲
  • 亞太地區
  • 拉丁美洲
  • 中東和非洲

第8章 競爭情勢

  • 公司分類
  • 策略規劃
    • 新生物標記的推出
    • 夥伴關係
    • 獲得
    • 合作
    • 資金籌措
  • 主要企業市佔率分析，2024 年
  • 公司熱力圖分析
  • 公司簡介
    • Thermo Fisher Scientific Inc.
    • Siemens Healthineers AG
    • BioPorto Diagnostics A/S
    • SEKISUI Medical Co., Ltd
    • BioMerieux SA
    • SphingoTec GmbH
    • Randox Laboratories Ltd
    • Beckman Coulter Inc.
    • QIAGEN NV
    • EKF Diagnostics Holdings plc
Product Code: GVR-4-68040-764-4

Renal Biomarkers Market Summary

The global renal biomarkers market size was estimated at USD 1,530.0 million in 2024 and is expected to reach USD 3,161.4 million by 2033, growing at a CAGR of 8.54% from 2025 to 2033. The rising prevalence of kidney disease particularly chronic kidney disease (CKD) and acute kidney injury (AKI) along with the urgent clinical need for earlier and more nuanced detection beyond conventional measures.

CKD often remains asymptomatic until advanced stages, and biomarkers that can reveal subclinical pathology or early injury are of growing interest. In the U.S., an estimated 35.5 million adults have chronic kidney disease (CKD), and a significant number are unaware of their condition. Globally, CKD affects around 850 million people, which is approximately 9% of the adult population. A 2024 study projects that by 2032, nearly 125 million people across eight major countries will have advanced CKD, a 25% increase since 2022. In April 2024, AstraZeneca's IMPACT CKD modeling study projected that by 2032, as many as 16.5% of the population across eight countries could be affected by chronic kidney disease (CKD), with advanced-stage cases potentially increasing by up to 59.3%. The findings, presented at the 2024 ISN World Congress of Nephrology (WCN'24) in Buenos Aires, underscored the escalating global health challenge posed by CKD and emphasized its significant economic and environmental consequences. The large and growing base of kidney disease patients ensures a continually rising demand for more sensitive, specific, and multiplex biomarker assays. In addition, co-morbidities such as diabetes, hypertension, and aging populations further exacerbate kidney stress, pushing clinicians and payers to adopt advanced biomarkers (e.g. NGAL, KIM-1, cystatin C) earlier in the disease continuum to improve prognostics, therapy stratification, and monitoring. The high rate of undiagnosed early CKD (sometimes up to 90 % of cases go unnoticed until functional decline) underscores the latent market potential for tools that reliably flag early damage before conventional metrics (eGFR, creatinine) deviate significantly.

One of the most compelling opportunities in the renal biomarker landscape lies in emerging markets-Asia, Latin America, Africa where rising incidence of hypertension, diabetes, and aging populations is intensifying the renal disease burden, yet diagnostic infrastructure remains underdeveloped. As diagnostics penetration is still relatively low in many of these geographies, the entry of affordable, point-of-care biomarker platforms offers a high-growth niche. For example, Sphingotec's collaborations (e.g. with Beckman Coulter) to release penKid assays on standard clinical lab platforms reflect how a biomarker originally confined to research can scale into broader clinical adoption. (See news of licensing and launch of penKid in central labs) The capacity to deploy multiplex panels, low-volume assays, or simpler rapid tests in decentralized settings could help bridge diagnostic gaps in underserved regions.

Meanwhile, platform diversity is growing enzyme-linked immunosorbent assays (ELISA) still command a significant share, but more sensitive chemiluminescent immunoassays, multiplex panels, mass spectrometry (LC-MS), microfluidics, and point-of-care immunodiagnostic devices are gaining traction. For instance, the penKid assay's adoption on Beckman Coulter immunoassay platforms exemplifies how a novel biomarker can be integrated lab workflows. In research settings, microfluidic and multi-omics platforms will support novel discovery and multiplex panels opening scope for biomarker companies to offer value-added analytics, software, and interpretation services.

Global Renal Biomarkers Market Report Segmentation

This report forecasts revenue growth and provides an analysis of the latest trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global renal biomarkers market based on biomarker, diagnostic technique, end use, and region:

  • Biomarkers Outlook (Revenue, USD Million, 2021 - 2033)
  • Kits and reagents
  • Functional Biomarkers
    • Serum Creatinine
    • Blood Urea Nitrogen (BUN)
    • Estimated Glomerular Filtration Rate (eGFR)
  • Upregulated Proteins
    • Kidney Injury Molecule-1 (KIM-1)
    • Neutrophil Gelatinase-Associated Lipocalin (NGAL)
    • Cystatin C
    • Interleukin-18 (IL-18)
    • Others
  • Other Novel Biomarkers
    • microRNA biomarkers
    • Proteomic/metabolomic markers
  • Diagnostic technique/Platform Outlook (Revenue, USD Million, 2021 - 2033)
  • Enzyme-Linked Immunosorbent Assay (ELISA)
  • Immunoassays
  • Clinical Chemistry Assays
  • Point-of-Care Testing (POCT) Devices
  • Molecular Diagnostics
  • Other Emerging Platforms
  • End Use Outlook (Revenue, USD Million, 2021 - 2033)
  • Hospitals & Clinics
  • Diagnostic Laboratories
  • Academic & Research Institutes
  • Pharmaceutical & Biotechnology Companies
  • Others
  • Regional Outlook (Revenue, USD Million, 2021 - 2033)
  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • UK
    • Germany
    • France
    • Italy
    • Spain
    • Denmark
    • Sweden
    • Norway
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • South Korea
    • Thailand
  • Latin America
    • Brazil
    • Argentina
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE
    • Kuwait

Table of Contents

Chapter 1. Renal Biomarkers Market: Methodology and Scope

  • 1.1. Market Segmentation and Scope
    • 1.1.1. Segment Definitions
      • 1.1.1.1. Biomarkers Segment
      • 1.1.1.2. Diagnostic Technique/Platform Segment
      • 1.1.1.3. End Use Segment
  • 1.2. Regional Scope
  • 1.3. Estimates and Forecast Timeline
  • 1.4. Objectives
    • 1.4.1. Objective - 1
    • 1.4.2. Objective - 2
    • 1.4.3. Objective - 3
  • 1.5. Research Methodology
  • 1.6. Information Procurement
    • 1.6.1. Purchased Database
    • 1.6.2. GVR's Internal Database
    • 1.6.3. Secondary Sources
    • 1.6.4. Primary Research
  • 1.7. Information or Data Analysis
    • 1.7.1. Data Analysis Models
  • 1.8. Market Formulation & Validation
  • 1.9. Model Details
    • 1.9.1. Commodity Flow Analysis
  • 1.10. List of Secondary Sources
  • 1.11. List of Abbreviations

Chapter 2. Renal Biomarkers Market: Executive Summary

  • 2.1. Market Snapshot
  • 2.2. Segment Snapshot
  • 2.3. Competitive Landscape Snapshot

Chapter 3. Renal Biomarkers Market Variables, Trends, & Scope

  • 3.1. Market Segmentation and Scope
  • 3.2. Market Lineage Outlook
    • 3.2.1. Parent Market Outlook
    • 3.2.2. Related/Ancillary Market Outlook
  • 3.3. Market Dynamics
    • 3.3.1. Market driver analysis
      • 3.3.1.1. Rising prevalence of kidney diseases:
      • 3.3.1.2. Government Initiatives and Health Awareness Programs
      • 3.3.1.3. Technological advancements in kidney diagnostics
    • 3.3.2. Market restraint analysis
      • 3.3.2.1. High cost of diagnostics test
      • 3.3.2.2. Limited availability of trained personnel to perform and interpret biomarker tests
  • 3.4. Global Biomarker-Based Immunoassays Market Analysis Tools
    • 3.4.1. Industry Analysis - Porter's
    • 3.4.2. PESTEL Analysis

Chapter 4. Renal Biomarkers Market: Biomarkers Estimates & Trend Analysis

  • 4.1. Renal Biomarkers Market: Biomarkers Movement Analysis
  • 4.2. Kits and assays
    • 4.2.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 4.3. Reagents
    • 4.3.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 4.4. Services
    • 4.4.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 4.5. Functional Biomarkers
    • 4.5.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 4.5.2. Serum Creatinine
      • 4.5.2.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 4.5.3. Blood Urea Nitrogen (BUN)
      • 4.5.3.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 4.5.4. Estimated Glomerular Filtration Rate (eGFR)
      • 4.5.4.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 4.6. Upregulated Proteins
    • 4.6.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 4.6.2. Kidney Injury Molecule-1 (KIM-1)
      • 4.6.2.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 4.6.3. Neutrophil Gelatinase-Associated Lipocalin (NGAL)
      • 4.6.3.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 4.6.4. Cystatin C
      • 4.6.4.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 4.6.5. Interleukin-18 (IL-18)
      • 4.6.5.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 4.6.6. Others
      • 4.6.6.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 4.7. Other Novel Biomarkers
    • 4.7.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 4.7.2. microRNA biomarkers
      • 4.7.2.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 4.7.3. Proteomic/metabolomic markers
      • 4.7.3.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 5. Renal Biomarkers Market: Diagnostic Technique/Platform Estimates & Trend Analysis

  • 5.1. Renal Biomarkers Market: Diagnostic Technique/Platform Movement Analysis
  • 5.2. Enzyme-Linked Immunosorbent Assay (ELISA)
    • 5.2.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 5.3. Molecular Diagnostics
    • 5.3.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 5.4. Immunoassays
    • 5.4.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 5.5. Clinical Chemistry Assays
    • 5.5.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 5.6. Point-of-Care Testing (POCT) Devices
    • 5.6.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 5.7. Other Emerging Platforms
    • 5.7.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 6. Renal Biomarkers Market: End Use Estimates & Trend Analysis

  • 6.1. Renal Biomarkers Market: End Use Movement Analysis
  • 6.2. Hospitals and clinics
    • 6.2.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.3. Diagnostics Laboratories
    • 6.3.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.4. Academic & Research Institutes
    • 6.4.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.5. Pharmaceutical & Biotechnology Companies
    • 6.5.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.6. Others
    • 6.6.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 7. Renal Biomarkers Market: Regional Business Analysis

  • 7.1. Regional Market Snapshot
  • 7.2. North America
    • 7.2.1. North America Renal Biomarkers Market Estimates And Forecast, 2021 - 2033 (USD Million)
    • 7.2.2. U.S.
      • 7.2.2.1. U.S. Renal Biomarkers Market, 2021 - 2033 (USD Million)
      • 7.2.2.2. Key Country Dynamics
      • 7.2.2.3. Regulatory Framework
      • 7.2.2.4. Reimbursement Scenario
      • 7.2.2.5. Competitive Scenario
    • 7.2.3. Canada
      • 7.2.3.1. Canada Renal Biomarkers Market, 2021 - 2033 (USD Million)
      • 7.2.3.2. Key Country Dynamics
      • 7.2.3.3. Regulatory Framework
      • 7.2.3.4. Reimbursement Scenario
      • 7.2.3.5. Competitive Scenario
    • 7.2.4. Mexico
      • 7.2.4.1. Mexico Renal Biomarkers Market, 2021 - 2033 (USD Million)
      • 7.2.4.2. Key Country Dynamics
      • 7.2.4.3. Regulatory Framework
      • 7.2.4.4. Reimbursement Scenario
      • 7.2.4.5. Competitive Scenario
  • 7.3. Europe
    • 7.3.1. Europe Renal Biomarkers Market, 2021 - 2033 (USD Million)
    • 7.3.2. UK
      • 7.3.2.1. UK Renal Biomarkers Market, 2021 - 2033 (USD Million)
      • 7.3.2.2. Key Country Dynamics
      • 7.3.2.3. Regulatory Framework
      • 7.3.2.4. Reimbursement Scenario
      • 7.3.2.5. Competitive Scenario
    • 7.3.3. Germany
      • 7.3.3.1. Germany Renal Biomarkers Market, 2021 - 2033 (USD Million)
      • 7.3.3.2. Key Country Dynamics
      • 7.3.3.3. Regulatory Framework
      • 7.3.3.4. Reimbursement Scenario
      • 7.3.3.5. Competitive Scenario
    • 7.3.4. Spain
      • 7.3.4.1. Spain Renal Biomarkers Market, 2021 - 2033 (USD Million)
      • 7.3.4.2. Key Country Dynamics
      • 7.3.4.3. Regulatory Framework
      • 7.3.4.4. Reimbursement Scenario
      • 7.3.4.5. Competitive Scenario
    • 7.3.5. France
      • 7.3.5.1. France Renal Biomarkers Market, 2021 - 2033 (USD Million)
      • 7.3.5.2. Key Country Dynamics
      • 7.3.5.3. Regulatory Framework
      • 7.3.5.4. Reimbursement Scenario
      • 7.3.5.5. Competitive Scenario
    • 7.3.6. Italy
      • 7.3.6.1. Italy Renal Biomarkers Market, 2021 - 2033 (USD Million)
      • 7.3.6.2. Key Country Dynamics
      • 7.3.6.3. Regulatory Framework
      • 7.3.6.4. Reimbursement Scenario
      • 7.3.6.5. Competitive Scenario
    • 7.3.7. Denmark
      • 7.3.7.1. Denmark Renal Biomarkers Market, 2021 - 2033 (USD Million)
      • 7.3.7.2. Key Country Dynamics
      • 7.3.7.3. Regulatory Framework
      • 7.3.7.4. Reimbursement Scenario
      • 7.3.7.5. Competitive Scenario
    • 7.3.8. Sweden
      • 7.3.8.1. Sweden Renal Biomarkers Market, 2021 - 2033 (USD Million)
      • 7.3.8.2. Key Country Dynamics
      • 7.3.8.3. Regulatory Framework
      • 7.3.8.4. Reimbursement Scenario
      • 7.3.8.5. Competitive Scenario
    • 7.3.9. Norway
      • 7.3.9.1. Norway Renal Biomarkers Market, 2021 - 2033 (USD Million)
      • 7.3.9.2. Key Country Dynamics
      • 7.3.9.3. Regulatory Framework
      • 7.3.9.4. Reimbursement Scenario
      • 7.3.9.5. Competitive Scenario
  • 7.4. Asia Pacific
    • 7.4.1. Asia-Pacific Renal Biomarkers Market, 2021 - 2033 (USD Million)
    • 7.4.2. Japan
      • 7.4.2.1. Japan Renal Biomarkers Market, 2021 - 2033 (USD Million)
      • 7.4.2.2. Key Country Dynamics
      • 7.4.2.3. Regulatory Framework
      • 7.4.2.4. Reimbursement Scenario
      • 7.4.2.5. Competitive Scenario
    • 7.4.3. China
      • 7.4.3.1. China Renal Biomarkers Market, 2021 - 2033 (USD Million)
      • 7.4.3.2. Key Country Dynamics
      • 7.4.3.3. Regulatory Framework
      • 7.4.3.4. Reimbursement Scenario
      • 7.4.3.5. Competitive Scenario
    • 7.4.4. India
      • 7.4.4.1. India Renal Biomarkers Market, 2021 - 2033 (USD Million)
      • 7.4.4.2. Key Country Dynamics
      • 7.4.4.3. Regulatory Framework
      • 7.4.4.4. Reimbursement Scenario
      • 7.4.4.5. Competitive Scenario
    • 7.4.5. South Korea
      • 7.4.5.1. South Korea Renal Biomarkers Market, 2021 - 2033 (USD Million)
      • 7.4.5.2. Key Country Dynamics
      • 7.4.5.3. Regulatory Framework
      • 7.4.5.4. Reimbursement Scenario
      • 7.4.5.5. Competitive Scenario
    • 7.4.6. Thailand
      • 7.4.6.1. Thailand Renal Biomarkers Market, 2021 - 2033 (USD Million)
      • 7.4.6.2. Key Country Dynamics
      • 7.4.6.3. Regulatory Framework
      • 7.4.6.4. Reimbursement Scenario
      • 7.4.6.5. Competitive Scenario
    • 7.4.7. Australia
      • 7.4.7.1. Australia Renal Biomarkers Market, 2021 - 2033 (USD Million)
      • 7.4.7.2. Key Country Dynamics
      • 7.4.7.3. Regulatory Framework
      • 7.4.7.4. Reimbursement Scenario
      • 7.4.7.5. Competitive Scenario
  • 7.5. Latin America
    • 7.5.1. Latin America Renal Biomarkers Market, 2021 - 2033 (USD Million)
    • 7.5.2. Brazil
      • 7.5.2.1. Brazil Renal Biomarkers Market, 2021 - 2033 (USD Million)
      • 7.5.2.2. Key Country Dynamics
      • 7.5.2.3. Regulatory Framework
      • 7.5.2.4. Reimbursement Scenario
      • 7.5.2.5. Competitive Scenario
    • 7.5.3. Argentina
      • 7.5.3.1. Argentina Renal Biomarkers Market, 2021 - 2033 (USD Million)
      • 7.5.3.2. Key Country Dynamics
      • 7.5.3.3. Regulatory Framework
      • 7.5.3.4. Reimbursement Scenario
      • 7.5.3.5. Competitive Scenario
  • 7.6. MEA
    • 7.6.1. MEA Renal Biomarkers Market, 2021 - 2033 (USD Million)
    • 7.6.2. South Africa
      • 7.6.2.1. South Africa Renal Biomarkers Market, 2021 - 2033 (USD Million)
      • 7.6.2.2. Key Country Dynamics
      • 7.6.2.3. Regulatory Framework
      • 7.6.2.4. Reimbursement Scenario
      • 7.6.2.5. Competitive Scenario
    • 7.6.3. Saudi Arabia
      • 7.6.3.1. Saudi Arabia Renal Biomarkers Market, 2021 - 2033 (USD Million)
      • 7.6.3.2. Key Country Dynamics
      • 7.6.3.3. Regulatory Framework
      • 7.6.3.4. Reimbursement Scenario
      • 7.6.3.5. Competitive Scenario
    • 7.6.4. UAE
      • 7.6.4.1. UAE Renal Biomarkers Market, 2021 - 2033 (USD Million)
      • 7.6.4.2. Key Country Dynamics
      • 7.6.4.3. Regulatory Framework
      • 7.6.4.4. Reimbursement Scenario
      • 7.6.4.5. Competitive Scenario
    • 7.6.5. Kuwait
      • 7.6.5.1. Kuwait Renal Biomarkers Market, 2021 - 2033 (USD Million)
      • 7.6.5.2. Key Country Dynamics
      • 7.6.5.3. Regulatory Framework
      • 7.6.5.4. Reimbursement Scenario
      • 7.6.5.5. Competitive Scenario

Chapter 8. Competitive Landscape

  • 8.1. Company Categorization
  • 8.2. Strategy Mapping
    • 8.2.1. New Biomarkers Launch
    • 8.2.2. Partnerships
    • 8.2.3. Acquisition
    • 8.2.4. Collaboration
    • 8.2.5. Funding
  • 8.3. Key Company Market Share Analysis, 2024
  • 8.4. Company Heat Map Analysis
  • 8.5. Company Profiles
    • 8.5.1. Thermo Fisher Scientific Inc.
      • 8.5.1.1. Company Overview
      • 8.5.2.2. Financial Performance
      • 8.5.2.3. Biomarkers Benchmarking
      • 8.5.2.4. Strategic Initiatives
    • 8.5.2. Siemens Healthineers AG
      • 8.5.2.1. Company Overview
      • 8.5.2.2. Financial Performance
      • 8.5.2.3. Biomarkers Benchmarking
      • 8.5.2.4. Strategic Initiatives
    • 8.5.3. BioPorto Diagnostics A/S
      • 8.5.3.1. Company Overview
      • 8.5.3.2. Financial Performance
      • 8.5.3.3. Biomarkers Benchmarking
      • 8.5.3.4. Strategic Initiatives
    • 8.5.4. SEKISUI Medical Co., Ltd
      • 8.5.4.1. Company Overview
      • 8.5.4.2. Financial Performance
      • 8.5.4.3. Biomarkers Benchmarking
      • 8.5.4.4. Strategic Initiatives
    • 8.5.5. BioMerieux SA
      • 8.5.5.1. Company Overview
      • 8.5.5.2. Financial Performance
      • 8.5.5.3. Biomarkers Benchmarking
      • 8.5.5.4. Strategic Initiatives
    • 8.5.6. SphingoTec GmbH
      • 8.5.6.1. Company Overview
      • 8.5.6.2. Financial Performance
      • 8.5.6.3. Biomarkers Benchmarking
      • 8.5.6.4. Strategic Initiatives
    • 8.5.7. Randox Laboratories Ltd
      • 8.5.7.1. Company Overview
      • 8.5.7.2. Financial Performance
      • 8.5.7.3. Biomarkers Benchmarking
      • 8.5.7.4. Strategic Initiatives
    • 8.5.8. Beckman Coulter Inc.
      • 8.5.8.1. Company Overview
      • 8.5.8.2. Financial Performance
      • 8.5.8.3. Biomarkers Benchmarking
      • 8.5.8.4. Strategic Initiatives
    • 8.5.9. QIAGEN N.V.
      • 8.5.9.1. Company Overview
      • 8.5.9.2. Financial Performance
      • 8.5.9.3. Biomarkers Benchmarking
      • 8.5.9.4. Strategic Initiatives
    • 8.5.10. EKF Diagnostics Holdings plc
      • 8.5.10.1. Company Overview
      • 8.5.10.2. Financial Performance
      • 8.5.10.3. Biomarkers Benchmarking
      • 8.5.10.4. Strategic Initiatives

List of Tables

  • Table 1 List Of Secondary Sources
  • Table 2 List Of Abbreviation
  • Table 3 Global Renal Biomarkers Market, By Region, 2021 - 2033 (USD Million)
  • Table 4 Global Renal Biomarkers Market, By Biomarkers, 2021 - 2033 (USD Million)
  • Table 5 Global Renal Biomarkers Market, By Diagnostic Technique/Platform, 2021 - 2033 (USD Million)
  • Table 6 Global Renal Biomarkers Market, By End Use, 2021 - 2033 (USD Million)
  • Table 7 North America Renal Biomarkers Market, By Country, 2021 - 2033 (USD Million)
  • Table 8 North America Renal Biomarkers Market, By Biomarkers, 2021 - 2033 (USD Million)
  • Table 9 North America Renal Biomarkers Market, By Diagnostic Technique/Platform, 2021 - 2033 (USD Million)
  • Table 10 North America Renal Biomarkers Market, By End Use, 2021 - 2033 (USD Million)
  • Table 11 U.S. Renal Biomarkers Market, By Biomarkers, 2021 - 2033 (USD Million)
  • Table 12 U.S. Renal Biomarkers Market, By Diagnostic Technique/Platform, 2021 - 2033 (USD Million)
  • Table 13 U.S. Renal Biomarkers Market, By End Use, 2021 - 2033 (USD Million)
  • Table 14 Canada Renal Biomarkers Market, By Biomarkers, 2021 - 2033 (USD Million)
  • Table 15 Canada Renal Biomarkers Market, By Diagnostic Technique/Platform, 2021 - 2033 (USD Million)
  • Table 16 Canada Renal Biomarkers Market, By End Use, 2021 - 2033 (USD Million)
  • Table 17 Mexico Renal Biomarkers Market, By Biomarkers, 2021 - 2033 (USD Million)
  • Table 18 Mexico Renal Biomarkers Market, By Diagnostic Technique/Platform, 2021 - 2033 (USD Million)
  • Table 19 Mexico Renal Biomarkers Market, By End Use, 2021 - 2033 (USD Million)
  • Table 20 Europe Renal Biomarkers Market, By Country, 2021 - 2033 (USD Million)
  • Table 21 Europe Renal Biomarkers Market, By Biomarkers, 2021 - 2033 (USD Million)
  • Table 22 Europe Renal Biomarkers Market, By Diagnostic Technique/Platform, 2021 - 2033 (USD Million)
  • Table 23 Europe Renal Biomarkers Market, By End Use, 2021 - 2033 (USD Million)
  • Table 24 UK Renal Biomarkers Market, By Biomarkers, 2021 - 2033 (USD Million)
  • Table 25 UK Renal Biomarkers Market, By Diagnostic Technique/Platform, 2021 - 2033 (USD Million)
  • Table 26 UK Renal Biomarkers Market, By End Use, 2021 - 2033 (USD Million)
  • Table 27 Germany Renal Biomarkers Market, By Biomarkers, 2021 - 2033 (USD Million)
  • Table 28 Germany Renal Biomarkers Market, By Diagnostic Technique/Platform, 2021 - 2033 (USD Million)
  • Table 29 Germany Renal Biomarkers Market, By End Use, 2021 - 2033 (USD Million)
  • Table 30 France Renal Biomarkers Market, By Biomarkers, 2021 - 2033 (USD Million)
  • Table 31 France Renal Biomarkers Market, By Diagnostic Technique/Platform, 2021 - 2033 (USD Million)
  • Table 32 France Renal Biomarkers Market, By End Use, 2021 - 2033 (USD Million)
  • Table 33 Italy Renal Biomarkers Market, By Biomarkers, 2021 - 2033 (USD Million)
  • Table 34 Italy Renal Biomarkers Market, By Diagnostic Technique/Platform, 2021 - 2033 (USD Million)
  • Table 35 Italy Renal Biomarkers Market, By End Use, 2021 - 2033 (USD Million)
  • Table 36 Spain Renal Biomarkers Market, By Biomarkers, 2021 - 2033 (USD Million)
  • Table 37 Spain Renal Biomarkers Market, By Diagnostic Technique/Platform, 2021 - 2033 (USD Million)
  • Table 38 Spain Renal Biomarkers Market, By End Use, 2021 - 2033 (USD Million)
  • Table 39 Sweden Renal Biomarkers Market, By Biomarkers, 2021 - 2033 (USD Million)
  • Table 40 Sweden Renal Biomarkers Market, By Diagnostic Technique/Platform, 2021 - 2033 (USD Million)
  • Table 41 Sweden Renal Biomarkers Market, By End Use, 2021 - 2033 (USD Million)
  • Table 42 Norway Renal Biomarkers Market, By Biomarkers, 2021 - 2033 (USD Million)
  • Table 43 Norway Renal Biomarkers Market, By Diagnostic Technique/Platform, 2021 - 2033 (USD Million)
  • Table 44 Norway Renal Biomarkers Market, By End Use, 2021 - 2033 (USD Million)
  • Table 45 Denmark Renal Biomarkers Market, By Biomarkers, 2021 - 2033 (USD Million)
  • Table 46 Denmark Renal Biomarkers Market, By Diagnostic Technique/Platform, 2021 - 2033 (USD Million)
  • Table 47 Denmark Renal Biomarkers Market, By End Use, 2021 - 2033 (USD Million)
  • Table 48 Asia Pacific Renal Biomarkers Market, By Country, 2021 - 2033 (USD Million)
  • Table 49 Asia Pacific Renal Biomarkers Market, By Biomarkers, 2021 - 2033 (USD Million)
  • Table 50 Asia Pacific Renal Biomarkers Market, By Diagnostic Technique/Platform, 2021 - 2033 (USD Million)
  • Table 51 Asia Pacific Renal Biomarkers Market, By End Use, 2021 - 2033 (USD Million)
  • Table 52 Japan Renal Biomarkers Market, By Biomarkers, 2021 - 2033 (USD Million)
  • Table 53 Japan Renal Biomarkers Market, By Diagnostic Technique/Platform, 2021 - 2033 (USD Million)
  • Table 54 Japan Renal Biomarkers Market, By End Use, 2021 - 2033 (USD Million)
  • Table 55 China Renal Biomarkers Market, By Biomarkers, 2021 - 2033 (USD Million)
  • Table 56 China Renal Biomarkers Market, By Diagnostic Technique/Platform, 2021 - 2033 (USD Million)
  • Table 57 China Renal Biomarkers Market, By End Use, 2021 - 2033 (USD Million)
  • Table 58 India Renal Biomarkers Market, By Biomarkers, 2021 - 2033 (USD Million)
  • Table 59 India Renal Biomarkers Market, By Diagnostic Technique/Platform, 2021 - 2033 (USD Million)
  • Table 60 India Renal Biomarkers Market, By End Use, 2021 - 2033 (USD Million)
  • Table 61 Australia Renal Biomarkers Market, By Biomarkers, 2021 - 2033 (USD Million)
  • Table 62 Australia Renal Biomarkers Market, By Diagnostic Technique/Platform, 2021 - 2033 (USD Million)
  • Table 63 Australia Renal Biomarkers Market, By End Use, 2021 - 2033 (USD Million)
  • Table 64 Thailand Renal Biomarkers Market, By Biomarkers, 2021 - 2033 (USD Million)
  • Table 65 Thailand Renal Biomarkers Market, By Diagnostic Technique/Platform, 2021 - 2033 (USD Million)
  • Table 66 Thailand Renal Biomarkers Market, By End Use, 2021 - 2033 (USD Million)
  • Table 67 South Korea Renal Biomarkers Market, By Biomarkers, 2021 - 2033 (USD Million)
  • Table 68 South Korea Renal Biomarkers Market, By Diagnostic Technique/Platform, 2021 - 2033 (USD Million)
  • Table 69 South Korea Renal Biomarkers Market, By End Use, 2021 - 2033 (USD Million)
  • Table 70 Latin America Renal Biomarkers Market, By Country, 2021 - 2033 (USD Million)
  • Table 71 Latin America Renal Biomarkers Market, By Biomarkers, 2021 - 2033 (USD Million)
  • Table 72 Latin America Renal Biomarkers Market, By Diagnostic Technique/Platform, 2021 - 2033 (USD Million)
  • Table 73 Latin America Renal Biomarkers Market, By End Use, 2021 - 2033 (USD Million)
  • Table 74 Brazil Renal Biomarkers Market, By Biomarkers, 2021 - 2033 (USD Million)
  • Table 75 Brazil Renal Biomarkers Market, By Diagnostic Technique/Platform, 2021 - 2033 (USD Million)
  • Table 76 Brazil Renal Biomarkers Market, By End Use, 2021 - 2033 (USD Million)
  • Table 77 Argentina Renal Biomarkers Market, By Biomarkers, 2021 - 2033 (USD Million)
  • Table 78 Argentina Renal Biomarkers Market, By Diagnostic Technique/Platform, 2021 - 2033 (USD Million)
  • Table 79 Argentina Renal Biomarkers Market, By End Use, 2021 - 2033 (USD Million)
  • Table 80 MEA Renal Biomarkers Market, By Country, 2021 - 2033 (USD Million)
  • Table 81 MEA Renal Biomarkers Market, By Biomarkers, 2021 - 2033 (USD Million)
  • Table 82 MEA Renal Biomarkers Market, By Diagnostic Technique/Platform, 2021 - 2033 (USD Million)
  • Table 83 MEA Renal Biomarkers Market, By End Use, 2021 - 2033 (USD Million)
  • Table 84 South Africa Renal Biomarkers Market, By Biomarkers, 2021 - 2033 (USD Million)
  • Table 85 South Africa Renal Biomarkers Market, By Diagnostic Technique/Platform, 2021 - 2033 (USD Million)
  • Table 86 South Africa Renal Biomarkers Market, By End Use, 2021 - 2033 (USD Million)
  • Table 87 Saudi Arabia Renal Biomarkers Market, By Biomarkers, 2021 - 2033 (USD Million)
  • Table 88 Saudi Arabia Renal Biomarkers Market, By Diagnostic Technique/Platform, 2021 - 2033 (USD Million)
  • Table 89 Saudi Arabia Renal Biomarkers Market, By End Use, 2021 - 2033 (USD Million)
  • Table 90 UAE Renal Biomarkers Market, By Biomarkers, 2021 - 2033 (USD Million)
  • Table 91 UAE Renal Biomarkers Market, By Diagnostic Technique/Platform, 2021 - 2033 (USD Million)
  • Table 92 UAE Renal Biomarkers Market, By End Use, 2021 - 2033 (USD Million)
  • Table 93 Kuwait Renal Biomarkers Market, By Biomarkers, 2021 - 2033 (USD Million)
  • Table 94 Kuwait Renal Biomarkers Market, By Diagnostic Technique/Platform, 2021 - 2033 (USD Million)
  • Table 95 Kuwait Renal Biomarkers Market, By End Use, 2021 - 2033 (USD Million)

List of Figures

  • Fig. 1 Market research process
  • Fig. 2 Information procurement
  • Fig. 3 Market summary
  • Fig. 4 Market segmentation & scope
  • Fig. 5 Market size and growth prospects
  • Fig. 6 Global renal biomarkers market- Key market driver analysis
  • Fig. 7 Global renal biomarkers market - Key market restraint analysis
  • Fig. 8 Penetration & growth prospect mapping
  • Fig. 9 Global renal biomarkers market - Porter's analysis
  • Fig. 10 Global renal biomarkers market - PESTEL analysis
  • Fig. 11 Global renal biomarkers market Biomarkers outlook key takeaways
  • Fig. 12 Global renal biomarkers market: Biomarkers movement analysis
  • Fig. 13 Functional Biomarkers market estimates, 2021 - 2033 (USD Million)
  • Fig. 14 Serum Creatinine market estimates, 2021 - 2033 (USD Million)
  • Fig. 15 Blood Urea Nitrogen (BUN) market estimates, 2021 - 2033 (USD Million)
  • Fig. 16 Estimated Glomerular Filtration Rate (eGFR) market estimates, 2021 - 2033 (USD Million)
  • Fig. 17 Upregulated Proteins market estimates, 2021 - 2033 (USD Million)
  • Fig. 18 Kidney Injury Molecule-1 (KIM-1) market estimates, 2021 - 2033 (USD Million)
  • Fig. 19 Neutrophil Gelatinase-Associated Lipocalin (NGAL) market estimates, 2021 - 2033 (USD Million)
  • Fig. 20 Cystatin C market estimates, 2021 - 2033 (USD Million)
  • Fig. 21 Interleukin-18 (IL-18) market estimates, 2021 - 2033 (USD Million)
  • Fig. 22 Others market estimates, 2021 - 2033 (USD Million)
  • Fig. 23 Other Novel Biomarkers market estimates, 2021 - 2033 (USD Million)
  • Fig. 24 microRNA biomarkers market estimates, 2021 - 2033 (USD Million)
  • Fig. 25 Proteomic/metabolomic markers Global renal biomarkers market technology outlook key takeaways
  • Fig. 26 Global renal biomarkers market: diagnostic technique/platform movement analysis
  • Fig. 27 Immunoassays market estimates, 2021 - 2033 (USD Million)
  • Fig. 28 Molecular diagnostics market estimates, 2021 - 2033 (USD Million)
  • Fig. 29 ELISA market estimates, 2021 - 2033 (USD Million)
  • Fig. 30 Clinical chemistry assays market estimates, 2021 - 2033 (USD Million)
  • Fig. 31 POCT market estimates, 2021 - 2033 (USD Million)
  • Fig. 32 Global renal biomarkers market end use outlook key takeaways
  • Fig. 33 Global renal biomarkers market: end use movement analysis
  • Fig. 34 Hospitals and diagnostics laboratories market estimates, 2021 - 2033 (USD Million)
  • Fig. 35 Diagnostic laboratories market estimates, 2021 - 2033 (USD Million)
  • Fig. 36 Academic & Research Institutes market estimates, 2021 - 2033 (USD Million)
  • Fig. 37 Pharmaceutical & biotechnology companies market estimates, 2021 - 2033 (USD Million)
  • Fig. 38 Others market estimates, 2021 - 2033 (USD Million)
  • Fig. 39 Regional marketplace: Key takeaways
  • Fig. 40 Global Renal Biomarkers market: Regional movement analysis
  • Fig. 41 North America Renal Biomarkers market, 2021 - 2033 (USD Million)
  • Fig. 42 U.S. renal biomarkers market, 2021 - 2033 (USD Million)
  • Fig. 43 Canada renal biomarkers market, 2021 - 2033 (USD Million)
  • Fig. 44 Mexico renal biomarkers market, 2021 - 2033 (USD Million)
  • Fig. 45 Europe renal biomarkers market, 2021 - 2033 (USD Million)
  • Fig. 46 UK renal biomarkers market, 2021 - 2033 (USD Million)
  • Fig. 47 Germany renal biomarkers market, 2021 - 2033 (USD Million)
  • Fig. 48 France renal biomarkers market, 2021 - 2033 (USD Million)
  • Fig. 49 Spain renal biomarkers market, 2021 - 2033 (USD Million)
  • Fig. 50 Italy renal biomarkers market, 2021 - 2033 (USD Million)
  • Fig. 51 Denmark renal biomarkers market, 2021 - 2033 (USD Million)
  • Fig. 52 Sweden renal biomarkers market, 2021 - 2033 (USD Million)
  • Fig. 53 Norway renal biomarkers market, 2021 - 2033 (USD Million)
  • Fig. 54 Asia Pacific renal biomarkers market, 2021 - 2033 (USD Million)
  • Fig. 55 Japan renal biomarkers market, 2021 - 2033 (USD Million)
  • Fig. 56 China renal biomarkers market, 2021 - 2033 (USD Million)
  • Fig. 57 India renal biomarkers market, 2021 - 2033 (USD Million)
  • Fig. 58 South Korea renal biomarkers market, 2021 - 2033 (USD Million)
  • Fig. 59 Australia renal biomarkers market, 2021 - 2033 (USD Million)
  • Fig. 60 Thailand renal biomarkers market, 2021 - 2033 (USD Million)
  • Fig. 61 Latin America renal biomarkers market, 2021 - 2033 (USD Million)
  • Fig. 62 Brazil renal biomarkers market, 2021 - 2033 (USD Million)
  • Fig. 63 Argentina renal biomarkers market, 2021 - 2033 (USD Million)
  • Fig. 64 MEA renal biomarkers market, 2021 - 2033 (USD Million)
  • Fig. 65 South Africa renal biomarkers market, 2021 - 2033 (USD Million)
  • Fig. 66 Saudi Arabia renal biomarkers market, 2021 - 2033 (USD Million)
  • Fig. 67 UAE renal biomarkers market, 2021 - 2033 (USD Million)
  • Fig. 68 Kuwait renal biomarkers market, 2021 - 2033 (USD Million)
  • Fig. 69 Strategy framework